news roundup
KKS (Coordination Center for Clinical Trials) Düsseldorf, an academic center in Europe, has signed a multiyear agreement with OmniComm Systems, Inc., to use OmniComm's TrialMaster EDC technology to develop and conduct clinical trials at multiple sites. As a key division of the Faculty of Medicine at Heinrich Heine University, KKS supports clinical research trials undertaken at the institution.
| Advertisement Tell us what you think about clinical operations and receive a $5 Amazon gift card!
 TAKE THE SHORT SURVEY |
Advarra, provider of institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services in North America, has acquired Quorum IRB and its research and technology consulting division, Kinetiq.
| Advertisement RBM Case Studies: How Artificial Intelligence and Machine Learning with Advanced Analytics are driving new levels of patient safety and study quality
Thursday, March 28, 2019 11am EDT
 Register now |
Worldwide Clinical Trials, a full-service, midsize, global CRO, and Deep Lens, an AI-driven digital pathology company, announced a strategic alliance to pair Worldwide's clinical cancer research and global clinical trial operations capabilities with the Deep Lens VIPER™ digital pathology platform to present patients with treatment and clinical trial options earlier in the oncology care pathway.
| Advertisement
Fast, Focused Medical Data Review – Use Cases by a Medical Monitor
Wednesday, March 27, 2019 at 11am EDT| 8am PDT| 3pm GMT| 4pm CET
 Register now |
Almac Group announced Almac ONE™, a new clincal trial supply solution that aligns patient recruitment, clinical supply and IRT strategies to deliver a seamless data flow.
| Advertisement Minimizing the Impact of Human Error, Subjectivity, and Labor Costs
The Application of Digital Pathology in Clinical Trials
Tuesday, March 19, 2019 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
 Register now |
Articles
Challenges with temperature control of clinical supplies coupled with direct-to-patient trials is leading to new methods to ensure safe delivery.
Developing a precision medicine that relies on a companion diagnostic test (CDx)—a test based on biomarkers that prospectively predict likely responses—to stratify patients is becoming increasingly complex due to rapidly growing knowledge about tumor biology and the swift evolution of diagnostic technologies.
|
|
